Connect with us

Trends

Chemiluminescence analyzers market in India to grow at 6% CAGR

Chemiluminescence immunoassay (CLIA) analyzers are indispensable tools in Indian medical landscape, offering a broad spectrum of applications encompassing infectious disease testing and cancer biomarker analysis. Consequently, they play a pivotal role in enhancing healthcare delivery, facilitating disease management, and advancing public health initiatives in the country. Against this backdrop, India’s chemiluminescence analyzers market is expected to grow at a compound annual growth rate (CAGR) of around 6% through 2033, forecasts GlobalData, a leading data and analytics company.

GlobalData’s report, “Immunochemistry Analyzers Market Forecast to 2033,” reveals that India’s chemiluminescence analyzers market accounted for only around 2% of the Asia-Pacific market in 2023.

Strengthening the global foothold of Indian diagnostic companies in the CLIA analyzer segment necessitates strategic initiatives such as fostering international collaborations, which can enhance their presence and competitiveness.

Recently, Japan-based Fujirebio Inc and India-based Agappe Diagnostics Ltd have entered into an agreement of contract development and manufacturing organization (CDMO) partnership for cartridge-based CLIA system reagents manufacturing project for the immunology equipment Mispa i60 and Mispa i121. While Fujirebio will supply equipment and raw materials, Agappe will develop and manufacture dedicated reagents, meeting regulatory standards.

Shreya Jain, Medical Devices Analyst at GlobalData, comments: “Despite the limitations including technology dependency, limited R&D investment and market competition, India’s cost-effective manufacturing capabilities stemming from lower labor and operational expenses underscore its appeal as a manufacturing hub.
By combining the mutually complementary strengths of both companies, Agappe and Fujirebio can deliver high-quality CLIA solutions with cost competitiveness, contributing to healthcare advancement in India.”

Agappe and Fujirebio are set to launch the analyzers and reagents in June 2024 after significant progress, including signing a supply and license agreement in March 2023. Notably, these analyzers and reagents will be marketed under Agappe’s brand, marking Agappe as the first Indian company to offer a complete chemiluminescence solution with locally manufactured reagents.

Jain concludes: “The future holds immense potential for chemiluminescence analyzers to revolutionize patient care and clinical outcomes across various medical domains, owing to their sensitivity and specificity. Continued advancements in technology, supportive regulatory frameworks, and strategic collaborations between healthcare stakeholders will be pivotal in realizing the full potential of CLIA analyzers in India’s healthcare landscape.” GlobalData

Copyright © 2024 Medical Buyer

error: Content is protected !!